Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + anthracycline + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen comprising docetaxel, an anthracycline (such as doxorubicin or epirubicin), and cyclophosphamide. This regimen, commonly referred to as TAC or TEC, is a standard-of-care treatment for breast cancer, including triple-negative breast cancer (TNBC). Docetaxel is a taxane that stabilizes microtubules, inhibiting cell division. Anthracyclines act by intercalating into DNA and inhibiting topoisomerase II, while cyclophosphamide is an alkylating agent that cross-links DNA strands. The Affiliated Nanjing Drum Tower Hospital is utilizing this regimen in an observational study to investigate the characteristics of senescent T lymphocytes and their relationship with neoadjuvant chemotherapy efficacy in young TNBC patients.
- Brand names
- AdriamycinEllenceCytoxan
- Other names
- docetaxel + doxorubicin + cyclophosphamidedocetaxel + epirubicin + cyclophosphamideTAC regimenTEC regimendocetaxel + anthracycline + cyclophosphamide-The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School-triple-negative breast cancer
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on docetaxel + anthracycline + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + anthracycline + cyclophosphamide.